# Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

> **NCT00098280** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 75 (—)

## Conditions studied

- Hemoglobinuria, Paroxysmal

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT00098280
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 75 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098280, "Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00098280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*